Ibrutinib in primary central nervous system diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Ibrutinib in primary central nervous system diffuse large B-cell lymphoma

Published:2020-03-01 Issue:1 Volume:9 Page:
ISSN:2045-0907
Container-title:CNS Oncology
language:en
Short-container-title:CNS Oncology

Author:

T Low Justin¹,B Peters Katherine¹²^ORCID

Affiliation:

1. Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA

2. Department of Neurology, The Preston Robert Tisch Brain Tumor Center, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA

Abstract

The standard regimen for the treatment of newly diagnosed primary CNS lymphoma (PCNSL) remains regimens that contain high-dose methotrexate (MTX). While these regimens can provide control for some patients, there is a dearth of options for the treatment of patients with PCNSL who cannot tolerate MTX-containing regimens, or whose cancers are refractory to MTX. In this article, we review a promising new option; ibrutinib, a Bruton tyrosine kinase inhibitor, for patients with relapsed and refractory PCNSL.

Publisher

Future Medicine Ltd

Subject

General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cns-2019-0022

Reference65 articles.

1. American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012

2. Intraocular lymphoma 2000–2005: results of a retrospective multicentre trial

3. Mechanisms and Effects of Loss of Human Leukocyte Antigen Class II Expression in Immune-Privileged Site-Associated B-Cell Lymphoma

4. Radiation therapy for localized low-grade non-Hodgkin's lymphomas

5. Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation therapy Oncology Group (RTOG): RTOG 8315

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First use of ibrutinib for the treatment of post‐transplant central nervous system graft‐versus‐host disease;British Journal of Haematology;2023-06-26

2. Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review;Frontiers in Oncology;2022-11-17

3. Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review;Neurology International;2022-01-11

4. Ribonucleotide Reductase Regulatory Subunit M2 as a Driver of Glioblastoma TMZ-Resistance through Modulation of dNTP Production;2021-11-24

5. Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia;Cancers;2021-10-29